New dietary ingredient notifications
This article was originally published in The Tan Sheet
Executive SummaryFDA should issue a guidance to explain when new dietary ingredient notifications are necessary, as well as the type of information they should include, NNFA says in May 9 letter to the agency. Guidance should establish "whether, and under what conditions, a dietary ingredient that is a component of food (i.e. lycopene in tomatoes) would be exempt" from notification, as well as the quantity, quality of information required to satisfy the "history of use or other evidence of safety" standard. NNFA's comments respond to March 19 FDA notice requesting public feedback on premarket notification process for new dietary ingredients...
You may also be interested in...
ICER president Steve Pearson is ‘cautiously optimistic’ that net pricing for acute migraine treatments will align with benefits once discounts are factored in.
Almost 50 novel agents are already under review at FDA for potential 2020 approval. Candidates are notably diverse, with concentrations in established strongholds (oncology, neuroscience), popular programs (breakthrough), and powerhouse sponsors (keep an eye on Bristol-Myers Squibb right out of the gate).
CBER is starting the year with four novel gene and cell therapy applications under review and rolling submissions underway for more.